Skip to main content
OpenTrials
Completed

NCT Number: NCT00871871

Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)

This study will measure and compare changes in insulin production and sensitivity using the hyperglycemic clamp technique in obese patients with impaired glucose tolerance and hypertension treated with placebo, isosorbide mononitrate (ISMN) or hydrochlorothiazide (HCTZ).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

35 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female participants must be post-menopausal
  • Body Mass Index (BMI) of at least 29 kg/m^2
  • Weight has been stable over the past 3 months
  • Has never been treated for hypertension or is diagnosed with hypertension taking up to 2 anti-hypertensive medications
  • Willing to stop hypertension treatment for 14 days prior to randomization and throughout the study
  • Does not have a history of diabetes
  • In good health with the exception of hypertension
  • No history of abnormal heart rhythms
  • Part I only: willing to comply with high potassium/low sodium diet for the duration of the study
  • Willing to avoid strenuous physical activity during the study
  • Nonsmoker and/or has not used nicotine for at least 3 months and agrees to refrain from use of tobacco-containing products throughout the study
  • Agrees to refrain from consuming alcohol and caffeine during in-patient periods and to limit consumption at all other times during the study
  • Agrees not to consume grapefruit, grapefruit products, and citrus, apple, and pineapple juices 2 weeks prior to administration of the first dose of study drug

Exclusion criteria

  • History of any illness that may make their participation in the study unsafe or confuse the study results
  • Taking spironolactone or eplerenone
  • Cannot refrain from using any prescription or non-prescription drugs during the study
  • On a weight loss program and is not in the maintenance phase
  • Started a weight loss drug within 8 weeks of the first study visit
  • Consumes excessive amounts of alcohol or caffeine
  • Has had major surgery, donated or lost 1 unit of blood within 4 weeks of the first study visit
  • History of multiple and/or severe allergies to drugs or food
  • Is dehydrated

Treatment and study plan

Hydrochlorothiazide (HCTZ)

Drug

HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.

Other names: HCTZ

Comparator: Placebo to HCTZ

Drug

Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period

Isosorbide mononitrate (ISMN)

Drug

ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period

Comparator: Placebo to ISMN

Drug

Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period

Primary outcomes

  1. Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT)

    Time frame: 90 -120 minutes post-dose

    Steady state was defined as 90-120 minutes post-dose. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening.

  2. Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Fasting Glucose (IFG)

    Time frame: 90 -120 minutes post-dose

    Steady state was defined as 90-120 minutes post-dose. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening.

  3. Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants Who Had Normal Glucose Tolerance (NGT)

    Time frame: 90 -120 minutes post-dose

    Steady state was defined as 90-120 minutes post-dose. NGT participants (FPG <100 mg/dL & 2 hour plasma glucose (PG) <140 mg/dL during a 75g oral glucose tolerance test (OGTT) at screening) were neither Impaired Glucose Tolerant (IGT) nor Impaired Fasting Glucose (IFG). IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. IFG was defined as FPG between 100 and 125 mg/dL at screening.

  4. Part II: Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady-state

    Time frame: 90 -120 minutes post-dose

    Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes.

Secondary outcomes

  1. Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Glucose Tolerant (IGT)

    Time frame: 90 -120 minutes post-dose

    Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening.

  2. Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Fasting Glucose (IFG)

    Time frame: 90 -120 minutes post-dose

    Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening.

  3. Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Normal Glucose Tolerant (NGT)

    Time frame: 90 -120 minutes post-dose

    Steady state was defined as 90-120 minutes post-dose. The ratio was the measure of the quantity of glucose disposed per unit of plasma insulin concentration (PIC). Approximate PIC was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals, time = 90, 100, 110, and 120 minutes. NGT participants (FPG <100 mg/dL & 2 hour PG <140 mg/dL during a 75g OGTT at screening) were neither IGT nor IFG at screening. IGT - defined as a 2 hour PG >= 140 and <= 199 mg/dL during a 75g OGTT at screening. IFG - defined as FPG between 100 and 125 mg/dL at screening.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Evaluate the Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis in Obese Patients With Hypertension

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Mar 30, 2009
Registry last updated
Jul 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.